PD-L1 as a predictive factor for non-small-cell lung cancer prognosis

In The Lancet Oncology, Bernardo Haddock Lobo Goulart and colleagues 1 Goulart BHL Mushti SL Chatterjee S et al. Correlations of response rate and progression free survival with overall survival in immunotherapy trials for metastatic nonsmall-cell lung cancer: an FDA pooled analysis. Lancet Oncol. 2024; 25: 455-462 Summary Full Text Full Text PDF PubMed Scopus (0) Google Scholar conducted a pooled analysis of correlations of overall response rate and progression-free survival with overall survival in trials of immune checkpoint inhibitors (ICIs) for metastatic non-small-cell lung cancer. The results showed that the correlations of overall response rate and progression-free survival with overall survival were generally moderate. Moreover, the authors focused on evaluating the correlation between PD-L1 expression (PD-L1 tumour proportion score <1%, 1–49%, and ≥50%) and prognosis, and found that the correlations ranged from weak to moderate when evaluating subgroups by PD-L1 expression. This indicates that the predicted value of PD-L1 for prognosis of non-small-cell lung cancer treated with ICI-based regimens remains very unstable. Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysisCorrelations of overall response rate and progression-free survival with overall survival were generally moderate in this pooled analysis. The findings support routine analysis of mature overall survival data, where feasible, in first-line randomised trials of ICIs for metastatic NSCLC. Full-Text PDF